Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials
Top Cited Papers
- 9 November 2006
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 21 (1) , 151-157
- https://doi.org/10.1038/sj.leu.2404442
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 studyBlood, 2006
- The Ubiquitin-Proteasome Pathway and Its Role in CancerJournal of Clinical Oncology, 2005
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- A phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBritish Journal of Haematology, 2004
- Chromosome 13 Deletion/Hypodiploidy and Prognosis in Multiple Myeloma PatientsLeukemia & Lymphoma, 2004
- Determination of chromosome 13 status in bone marrow cells of patients with multiple myeloma using combined morphologic and fluorescence in situ hybridization analysisExperimental Hematology, 2004
- Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletionZeitschrift für Krebsforschung und Klinische Onkologie, 2003
- Graft versus myeloma may overcome the unfavorable effect of deletion of chromosome 13 in multiple myelomaBlood, 2003
- Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization‐defined chromosome 13 deletion in multiple myeloma: early results of total therapy IIBritish Journal of Haematology, 2002